Group 1: Company Overview - Da An Gene has focused on molecular diagnostic technology since its establishment, achieving significant research results and numerous product certifications [1] - The company provides reliable diagnostic solutions for clinical and related fields, with many products widely applied to safeguard public health [1] Group 2: Financial Performance - Da An Gene raised approximately 160 million during its IPO and has not conducted further financing since then [2] - Cumulative cash dividends exceed 4.5 billion since the company went public in 2004 [2] Group 3: Market Strategy - The company aims to strengthen collaborations with hospitals and medical institutions to better understand customer needs and provide more clinical diagnostic solutions [2] - Da An Gene will continue to invest in product research and development to enhance product cost-effectiveness and fulfill social responsibilities [2] Group 4: Competitive Advantage - Da An Gene has developed a complete, domestically leading nucleic acid testing technology supply chain, enabling rapid product development and large-scale production [2] - The company is committed to applying its products and technologies in clinical settings, distinguishing itself from other IVD companies [2]

证券代码：002030 证券简称：达安基因 广州达安基因股份有限公司投资者关系活动记录表 编号：2023010 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 □现场参观 □其他（） 国泰君安 孙超先 肖天莱 朱建华 王灿 参与单位名称及 元朔投资 梁艳仪 人员姓名 时间 2023-11-23（上午10:15-上午 11:30） 地点 广州市高新技术开发区科学城香山路19 号（公司总部） 上市公司接待人 董秘张斌、证券事务代表曾宇婷、投资者关系专员王平原 员姓名 调研公司经营和产品的情况（以调研机构提问，公司高管回答 的方式展开） 问题一：公司现在具有充足的现金流，是否考虑未来做一些并 ...

附件： 注：左三为公司董事会秘书张斌与调研人员合影留念。 ...

Group 1: Company Performance and Pricing Strategy - The initial price of the company's COVID-19 products was over 100 yuan, which has decreased to over 3 yuan after several rounds of large-scale procurement [1] - The company has maintained good financial performance despite the declining product prices [1][2] - The reduction in production costs is attributed to large-scale production and technological improvements, allowing for better cost control [2] Group 2: Market Share and Product Development - The company has achieved a market share of up to 60% for some products, maintaining a high market presence since its listing in 2004 [2] - The product range includes respiratory pathogens, influenza pathogens, gastrointestinal and foodborne pathogens, reproductive health, personalized tumor testing, and genetic testing [2] Group 3: Financial Outlook and Strategic Plans - The decline in profit during the third quarter was primarily due to product price adjustments and operational restructuring [2] - The company is cautiously optimistic about future investments and acquisitions, focusing on market trends and technological advancements [2] - There is a growing trend in the molecular market, with potential for molecular products to gradually replace immunological or biochemical products [2][3]

附件： 注：右四为公司董事会秘书张斌与调研人员合影留念。 ...

北京市康达（广州）律师事务所 关于广州达安基因股份有限公司 2023 年第一次临时股东大会的法律意见书 康达股会字[2023]第 0659 号 致：广州达安基因股份有限公司 北京市康达（广州）律师事务所（下称"本所"）接受广州达安基因股份有 限公司（下称"达安基因"或"公司"）委托，指派律师出席公司 2023 年第一 次临时股东大会。根据《中华人民共和国公司法》（下称"《公司法》"）、《中 华人民共和国证券法》（下称"《证券法》"）、《上市公司股东大会规则》（下 称"《股东大会规则》"）等法律、法规、规范性文件以及《广州达安基因股份 有限公司章程》（下称"达安基因《公司章程》"）的规定，本所律师对本次股 东大会的召集与召开程序、召集人和出席会议人员的资格、表决程序与表决结果 等事项进行见证并出具本法律意见书。 为出具本法律意见书，本所律师对达安基因本次股东大会所涉事宜进行了审 查，查阅了相关会议文件，并对有关事项进行了必要的核查和验证。本所律师同 意将本法律意见书作为达安基因本次股东大会公告材料，随同其他会议文件一并 公告，并依法对本法律意见书承担相应的责任。 本所律师根据相关法律、法规、规范性文件的要求，按 ...

特别提示： 1、本次股东大会未出现否决议案的情形。 证券代码：002030 证券简称：达安基因 公告编号：2023-045 广州达安基因股份有限公司 2023 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 2、本次股东大会未涉及变更前次股东大会决议。 3、本次股东大会以现场投票与网络投票相结合的方式召开。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： （1）现场会议召开时间：2023 年 11 月 15 日下午 14:30 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2023 年 11 月 15 日上午 9:15—9:25，9:30—11:30 和下午 13:00—15:00；通过 深圳证券交易所互联网投票系统投票的时间为 2023 年 11 月 15 日上午 9:15 至 2023 年 11 月 15 日下午 15:00 期间的任意时间。 2、会议召开地点：广州市高新技术开发区科学城香山路 19 号公司一楼讲学 厅 3、会议召开方式：现场投票与网络投票相结合的方式 4、会议召集人：公司 ...

证券代码：002030 证券简称：达安基因 公告编号：2023-044 广州达安基因股份有限公司 关于召开 2023 年第一次临时股东大会的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广州达安基因股份有限公司（以下简称"公司"）第八届董事会 2023 年第二 次临时会议决定于 2023 年 11 月 15 日（星期三）召开公司 2023 年第一次临时股 东大会，并在《证券时报》、《上海证券报》、巨潮资讯网刊登了《关于召开 2023 年第一次临时股东大会通知的公告》（公告编号：2023-043）。由于本次股东大会 将通过深圳证券交易所交易系统、互联网投票系统向社会公众股股东提供网络投 票平台，现将本次股东大会的有关事项再次提示如下： 一、召开股东大会的基本情况 1、股东大会届次：2023 年第一次临时股东大会 2、会议召集人：公司董事会 3、会议召开的合法、合规性：本次会议的召开符合有关法律、行政法规、 部门规章、规范性文件和《公司章程》的相关规定。 4、会议召开时间： （1）现场会议召开时间：2023 年 11 月 15 日下午 14:30 （ ...

附件： 注：左三为公司董事会秘书张斌与调研人员合影留念。 ...

Group 1: Company Overview and Financials - The company raised 160 million yuan during its IPO and has not pursued further financing or corporate bond issuance since then [2] - The company relies on self-sustained growth through scale production and continuous product innovation [2] Group 2: Market Adaptation and Policy Response - The introduction of the price negotiation and procurement policy is beneficial for innovative large-scale IVD companies, testing their adaptability to new market rules [1] - Product pricing will be influenced by national policies and market competition, with the company closely monitoring these factors [2] Group 3: Product Development and Export Strategy - The company has exported PCR products to over 140 countries, indicating a strong international presence and capacity [2] - The company is focusing on expanding its product line in the field of chemiluminescence and has entered the full IVD domain, emphasizing diagnostic technology and products [3] Group 4: Future Directions - The company aims to strengthen its position in PCR and molecular diagnostics while actively developing immunology, biochemistry, and analytical instruments [3] - The company is committed to becoming a "IVD World Factory" with a complete product chain and high cost-performance products [2]